Cargando…
Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments
Antimicrobial susceptibility testing, based on clinical breakpoints that incorporate pharmacokinetics/pharmacodynamics (PK/PD) and clinical outcomes, is becoming a new standard in guiding individual patient therapy as well as for drug resistance surveillance. However, for most antituberculosis drugs...
Autores principales: | Liu, Yongge, Moodley, Mischka, Pasipanodya, Jotam G., Gumbo, Tawanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112185/ https://www.ncbi.nlm.nih.gov/pubmed/36877034 http://dx.doi.org/10.1128/aac.01401-22 |
Ejemplares similares
-
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis
por: Rancoita, Paola M. V., et al.
Publicado: (2018) -
Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients
por: Reichmuth, Martina L., et al.
Publicado: (2020) -
Clinically and Microbiologically Derived Azithromycin Susceptibility Breakpoints for Salmonella enterica Serovars Typhi and Paratyphi A
por: Parry, Christopher M., et al.
Publicado: (2015) -
The pyrazinamide susceptibility breakpoint above which combination therapy fails
por: Gumbo, Tawanda, et al.
Publicado: (2014) -
A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground
por: Srivastava, Shashikant, et al.
Publicado: (2016)